Navigation Links
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
Date:5/28/2009

to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding the timing, progress and results of the clinical development, safety, regulatory processes, and commercialization efforts of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

This news release also contains forward-looking statements of OSI. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, OSI's and its collaborators' abilities to effectively market and sell Tarceva and to expand the
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.; OSI Pharmaceuticals; Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinsons Disease
2. The National Association of Boards of Pharmacy (NABP) Moves to Next Phase of Technician Recognition and Regulation
3. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
4. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
5. National Medical Interpreter Certification Testing Enters Pilot Phase
6. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
7. Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting
8. Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009
9. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
10. BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting
11. Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... (April 24, 2014) - Contact lenses coated with an antimicrobial ... infections, reports a study in Optometry and Vision ... of Optometry . The journal is published by ... Kluwer Health . , Studies in animals and now humans ... antimicrobial peptide melimine, according to the new research by Debarun ...
(Date:4/24/2014)... to be boring and irrelevant, could offer an alternative ... Researcher Dr Milena Furtado, and her team from the ... the heart cell fibroblast is a close relative to ... heart. , In research published today in Circulation ... are unique cells due to their genetic program, and ...
(Date:4/24/2014)... A Finnish team of researchers was the first in ... which is a tumour of the jaw. , Ameloblastoma ... recur after treatment. Ameloblastoma is most often found in ... by surgery, often resulting in tissue deficiencies in the ... suitable drug therapy could reduce the need for surgery ...
(Date:4/24/2014)... led by a scientist at the University of York ... in the development of the nervous system may also ... cancer., A research team, led by Dr Will ... of Biology at York, has studied how voltage-gated sodium ... channels are found in the membranes of excitable cells, ...
(Date:4/23/2014)... State University Spokane have developed a new way ... off behind the wheel. , Their recently patented ... more variable in drowsy driversand offers an affordable ... driver drowsiness detection systems. , Van Dongen"Video-based systems ... is drifting out of its lane are cumbersome ...
Breaking Medicine News(10 mins):Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Boring cells could hold the key to heart disease 2Health News:Breast cancer replicates brain development process 2Health News:WSU innovation improves drowsy driver detection 2
... painkillers during pregnancy increases the risk of miscarriage. ... are some of the most widely used drugs ... interviewed 1,055 pregnant women immediately after confirmation of ... their drug use since they became pregnant, reproductive ...
... researchers say giving heroin to opiate addicts can help ... the Netherlands conducted two separate studies of more than ... maintenance treatment. Participants were either injected with or inhaled ... they were enrolled.// ,The participants received either 12 ...
... soy in your diet: Research shows it may ... reports eating some phytoestrogens or estrogens found in ... ,The development of endometrial cancer is related to ... Phytoestrogens are oestrogen-like compounds which occur naturally //in ...
Indian shopkeepers reported a plunge in sales of Coca-Cola and Pepsi soft drinks Friday and some put out banners to deter buyers in a growing scare after an environment group said the beverages contai...
... could increase the risks of coronary heart disease in ... suffering from atherosclerosis, according to two studies released yesterday. ... the New England Journal of Medicine, expand on the ... estrogen-and-progestin-based hormone replacement therapy //to help combat heart disease. ...
... South Africa is entering the "death" phase as mortality ... devastating epidemic -- the world's worst -- and this ... President Thabo Mbeki's government has been criticized for its ... infected about 5 million South Africans.,Activists have also called ...
Cached Medicine News:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are ...
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that ... available in its catalogue: ... for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... Oct. 5, 2011 Callibra, Inc. dba Discharge 1-2-3 ... one of the 75 nominees for the 2011 Chicago Innovation ... and celebrated at an event at Chicago,s Harris Theater that ... year, is the Chicago region,s foremost recognition of the most ...
... Oct. 5, 2011 The National Organization for Rare ... have sent letters to key officials at the Food ... opportunities to provide input on decisions related to relative ... devices. (Logo: http://photos.prnewswire.com/prnh/20110719/DC37656LOGO-b ) ...
Cached Medicine Technology:Callibra, Inc. dba Discharge 1-2-3™ is Named Top 75 Nominee for 10th Annual Chicago Innovation Awards 2Patient Advocates Ask FDA to Let Them Help Define Risk 2Patient Advocates Ask FDA to Let Them Help Define Risk 3
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Medicine Products: